Breaking News
Get 50% Off 0
⭐ Start off 2025 with a powerful boost to your portfolio: January’s freshest AI-picked shares
Unlock shares
Close

Franklin Biotechnology Discovery Fund Class A (FBDIX)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
122.60 +0.98    +0.81%
03/01 - Closed. Currency in USD
  • Morningstar Rating:
  • Total Assets: 655.98M
Type:  Fund
Market:  United States
Issuer:  Franklin Templeton Investments
Asset Class:  Equity
Franklin Biotechnology Discovery A 122.60 +0.98 +0.81%

FBDIX Overview

 
On this page you'll find an in-depth profile of Franklin Biotechnology Discovery Fund Class A. Learn about the key management, total assets, investment strategy and contact information of FBDIX among other information.
Category

Health

Total Assets

655.98M

Expenses

1.04%

Inception Date

35688

Investment Strategy

The investment seeks capital appreciation. Under normal market conditions, the fund invests at least 80% of its net assets in securities of biotechnology companies and discovery research firms. The fund predominantly invests in equity securities. In addition to its investments in biotechnology companies, the fund may also invest up to 20% of its net assets in equity or debt securities of any type of issuer. It is non-diversified.

Contact Information

Address One Franklin Parkway, Building 970, 1st Floor
San Mateo,CA 94403
United States
Phone +1 650 3122000

Top Executives

Name Title Since Until
Akiva Felt - 2020 Now
Biography Mr. Felt has been a portfolio manager, providing research and advice on the purchases and sales of individual securities and portfolio risk assessment. He joined Franklin Templeton in 2018. Prior to joining Franklin Templeton, Mr. Felt was a Senior Research Analyst with Asymmetry Capital, a healthcare focused hedge fund. He has covered the biotechnology sector since 2007 in increasing capacities on the sell-side, most recently as Managing Director for Oppenheimer & Co.
Evan S. McCulloch Vice President 1997 Now
Biography Mr. McCulloch, CFA, joined Franklin Templeton Investments in 1992.
Wendy Lam Portfolio Manager 2018 2024
Biography Ms. Lam has joined Franklin Templeton Investments in 2016. Prior to joining Franklin Templeton, Ms. Lam was an Executive Director and Senior Analyst covering large-cap biotechnology for Oppenheimer & Co and had been an Equity Research Associate at Bank of America Merrill Lynch, Morgan Stanley and Oppenheimer & Co. Ms. Lam has a Ph.D degree.
Steven Kornfeld Portfolio Manager 2015 2020
Biography Steven Kornfeld is VP, Research Analyst and Portfolio Manager with Franklin Equity Group. He specializes in research analysis of the pharmaceutical industry and is a member of the Franklin Core/Hybrid team. Prior to joining Franklin Templeton Investments in January 2001, Mr. Kornfeld most recently worked in private equity and previously as a sell-side research analyst where he specialized in covering emerging growth companies. He holds an MBA from Northwestern University and a bachelor’s degree from the Wharton School of Business at the University of Pennsylvania. He is a CFA®* Charterholder.
Christopher Jay Lee Vice President 2016 2017
Biography Mr. Lee has two years of experience in investment management and heads up portfolio management for Separately Managed Accounts. Mr. Lee joined CBOE Vest in 2013. Prior to joining Vest, Mr. Lee was trading commodities in a family-owned portfolio. Mr. Lee is Chartered Financial Analyst and holds a bachelor’s degree in Electrical Engineering from University of California, Davis.
Jerel A. Banks senior equity research analyst 2012 2015
Biography JEREL A. Banks has been a portfolio manager of the Fund since September 2012, providing research and advice on the purchases and sales of individual securities and portfolio risk assessment. He joined Franklin Templeton Investments in 2012. Prior to joining Franklin Templeton Investments, he was a senior equity research analyst at Sectoral Asset Management and Apothecary Capital and an equity research associate at Capital Research and Management.
Vincent Xiang Manager 2004 2011
Biography Xiang is a manager of the fund providing research and advice on the purchases and sales of individual securities and portfolio risk assessment. He joined Franklin Templeton Investments in 2004. Previously, Xiang was a vice president of business development at Genyous Life Sciences, Inc. He also worked on deal sourcing, due diligence and strategic planning at BioAdvance and as a senior analyst for Acacia Research Corporation.
Jake Nunn Portfolio Manager, health-care Research Analyst 2000 2001
Biography Nunn is a portfolio manager and health-care research analyst with Franklin Advisors.
Paul Walker - 2000 2001
Biography Walker joined Franklin in 1996 with a degree in biotechnology and cell biology.
Kurt von Emster Portfolio Manager 1997 2000
Biography Von Emster is currently a portfolio manager with Franklin Advisers. He joined the firm in 1989 as a management trainee and securities analyst. Previously, he was a purchasing agent for the University of California at Santa Barbara's Marine Science Institute. Von Emster is a Chartered Financial Analyst and a member of the Security Analysts of San Francisco.
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

FBDIX Comments

Write your thoughts about Franklin Biotechnology Discovery Fund Class A
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email